Evidence map›Paper›PMID 40274065›Full record

SynthesisJournal of the American Academy of Child and Adolescent Psychiatry2026

Systematic Review: Antipsychotic Medication in Pregnancy and Neurodevelopmental Outcomes in Children.

Carly A Kaplan, Eline M P Poels, Marion I van den Heuvel, Hilmar H Bijma, Veerle Bergink, Anna-Sophie Rommel, Thalia Robakis

Abstract readSystematic Review
In one paragraph

Synthesis in Journal of the American Academy of Child and Adolescent Psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Carly A KaplanIcahn School of Medicine at Mount Sinai, New York City, New York.
Eline M P PoelsErasmus University Medical Center, Rotterdam, the Netherlands.
Marion I van den HeuvelTranzo Scientific Center for Care and Wellbeing, Tilburg University, the Netherlands.
Hilmar H BijmaErasmus University Medical Center, Rotterdam, the Netherlands.
Veerle BerginkIcahn School of Medicine at Mount Sinai, New York City, New York.
Anna-Sophie RommelIcahn School of Medicine at Mount Sinai, New York City, New York.
Thalia RobakisErasmus University Medical Center, Rotterdam, the Netherlands. Electronic address: thalia.robakis@mssm.edu.

Funding

Relapse risk after Discontinuation of Antidepressants during Pregnancy (R-DAP study)R01MH122869 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Veerle Bergink · 2020 to 2026
$4.3M
Developmental effects of antenatal exposure to antipsychoticsR01HD111117 · NICHD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI THALIA K ROBAKIS · 2023 to 2026
$2.5M
NICHD NIH HHS R01 HD111117NIMH NIH HHS R01 MH122869
6 · The paper itself

Abstract

objectiveAntipsychotic medications are widely prescribed, including during pregnancy, and pregnant individuals worry about the potential sequelae for the child. Although antipsychotics do not seem to be teratogenic, the long-term neurodevelopmental impact of prenatal exposure remains unclear. A systematic review was conducted to determine if intrauterine antipsychotic exposure increases the risk of adverse neurodevelopmental outcomes.

methodA systematic search was performed in MEDLINE, Cochrane, Embase, and PsycINFO for studies published before September 7, 2024. We included original studies assessing cognitive, motor, behavioral, social, and psychiatric outcomes in children prenatally exposed to antipsychotics, excluding case reports, reviews, preclinical studies, and studies without a control group. Quality and risk of bias were assessed using the Newcastle-Ottawa Scale.

resultsOf 1,349 studies identified, full text of 56 was screened, and 16 were included in the review. The number of exposed participants ranged from 11 to >15,000. In the 8 studies assessing motor development, early motor delays were observed but did not persist into later childhood. Neurodevelopmental disorders were assessed in 7 studies. Crude estimates showed greater risk in exposed children, but after adjusting for confounders, most studies found no significant risk. The mean NOS score was 7.1.

conclusionTransient motor delays may be associated with antipsychotic use during pregnancy, although future studies adjusting for confounding factors should clarify this risk. After adjustment for confounders, the risk of neurodevelopmental disorders in school-age children does not seem to be increased. Studies with longer follow-up time are required to further investigate the risk of neurodevelopmental disorders. PLAIN LANGUAGE SUMMARY: This systematic review of research examines the mental, behavioral, and cognitive health outcomes of children whose mothers took antipsychotics during pregnancy. Sixteen articles were included in the review; the number of exposed participants in each study ranged from 11 to >15,000. The authors found that the majority of studies, especially those with longer-term follow-up and larger samples, did not identify increased neurodevelopmental problems in children who were exposed to antipsychotics during pregnancy. Some studies noted transient motor delays in exposed infants, but the authors found that they did not sufficiently account for the potential influence of severe maternal mental illness on this association. CLINICAL GUIDANCE: • Antipsychotic use during pregnancy may be indicated for effective treatment of severe mental illness in pregnant women. • A discussion that involves the risks of untreated maternal mental illness alongside existing data on antipsychotic exposure in pregnancy and its potential neurodevelopmental impact on children is an important step in supporting informed decision making. STUDY REGISTRATION INFORMATION: Neurodevelopmental Consequences of Antenatal Exposure to Antipsychotic Medication: A Systematic Review and Meta-Analysis; https://www.crd.york.ac.uk/PROSPERO/view/CRD42024499352.

Indexed as

Antipsychotic AgentsNeurodevelopmental DisordersPregnancy ComplicationsPrenatal Exposure Delayed EffectsChildChild, PreschoolFemaleHumansPregnancyAntipsychotic Agentsantipsychoticneurodevelopmentneurodevelopmental disordersoffspringpregnancy

Identifiers

PMID40274065
PMCPMC12949658

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.